Mirtazapine Sandoz (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonising postsynaptic 5‑HT2 and 5‑HT3 receptors while also inhibiting histamine H1 receptors. This combined action enhances serotonergic and noradrenergic neurotransmission, producing antidepressant and anxiolytic effects.

The appropriate dose of Mirtazapine Sandoz is determined individually by a qualified prescriber based on the patient’s clinical condition, response to therapy, and tolerability. Dosage adjustments are made according to professional medical guidance.

Safety data for Mirtazapine use in pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against possible risks and discuss any concerns with the patient. Use only if clearly needed and prescribed by a physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine often causes more sedation and weight gain but may be more effective for patients with prominent insomnia or loss of appetite. Its distinct receptor profile offers an alternative mechanism for those who do not respond to SSRIs or SNRIs.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain product stability.

Mirtazapine Sandoz is taken orally, usually once daily in the evening due to its sedative effect. It may be swallowed with or without food, but patients should follow the prescribing physician’s instructions for optimal absorption.

Serious risks include rare blood dyscrasias such as agranulocytosis, seizures, severe allergic reactions, hepatic dysfunction, and the emergence or worsening of suicidal thoughts, particularly at the start of therapy. Prompt medical attention is required if any of these occur.

Mirtazapine is contraindicated in patients with known hypersensitivity to the drug or any of its excipients, and in those currently taking monoamine oxidase inhibitors (MAOIs) unless a wash‑out period of at least 14 days has elapsed. Caution is advised for individuals with severe hepatic impairment or uncontrolled epilepsy.